NEUP Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 5.31%, SMA50 8.07%, SMA200 -38.66%). The stock’s 14-day RSI is 60.43 (firm momentum), while the ATR of 0.17 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -79.63% below its high and over 19.62% above its low. Average 10-day trading volume of 31.57 thousand shares is below the 3-month average of 45.53 thousand, indicating normal recent market interest.

Neuphoria Therapeutics Inc. generated EPS of -$23.89 over the past year. Five-year average earnings growth is -20.01%. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $35.00 to $21.00. The high target offers 564.14% upside. The low target suggests 298.48% downside. The mean target is $25.67. This offers 387.1% upside. Neuphoria Therapeutics Inc. earnings surprise history is a mixed track record. The quarter that ended February 17, 2026, missed forecasts by 37.5%. The prior quarter beat by 119.71%. Over the last six quarters, Apple has recorded several small beats. These include -99.59% in March 17, 2025.

Neuphoria Therapeutics Inc. has 5.39 million shares outstanding. The public float is 4.17 million shares, elevated short interest at 0.62% of float. This equals 33.19 thousand shares. The short ratio is 1.06 days. Institutional investors hold 53.92% of the float. Insiders own 7.72%.

Neuphoria Therapeutics Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $5.68. This means the shares are trading below this model’s fair value.

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) closed at $5.22 USD, losing -$0.05 (-0.95%) from the previous close of $5.27. The stock is currently mid-range between its 52-week high and low $3.65 and $21.40. With a market capitalization of about $28.14 million, Neuphoria Therapeutics Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.48). Key stats such as the average daily volume over the past year has been around 47.47 thousand shares, volume is running light vs its 52-week average. Headquartered in Burlington, None, Neuphoria Therapeutics Inc. operates in the Healthcare sector and the Medical - Pharmaceuticals industry. Led by CEO Spyridon Papapetropoulos, the company employs approximately 8 people and listed since December 16, 2021. Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders.

Neuphoria Therapeutics Inc. trades at a P/E ratio of -0.06, slightly below the S&P 500 average, with a price-to-sales ratio of 3.45 and a price-to-book ratio of 0.8 suggesting the stock is closer to book value. The P/FCF stands at 0.38, also above market averages.

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) shares are flat 3.87% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Neuphoria Therapeutics Inc. trading at a premium to the broader market with a P/E of -0.06. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $24.50, suggesting 364.9% upside. Our AI forecast model points to short-term strength (7.59% over two weeks), a medium-term fall (-79.32% over three months), and a longer-term loss (-73.62% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Neuphoria Therapeutics Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 7.59%, with price expected at $5.67 by May 14, 2026, within a range of $5.50 to $5.84 3-Month Outlook: Projected fall of -79.32%, reaching $1.09 by July 29, 2026, with a range of $0.55 to $1.39. 1-Year Outlook: Projected loss of -73.62%, with price at $1.39 by April 30, 2027, within a range of $0.00 to $0.64.